Premium
Incidence of inhibitors in patients with severe and moderate hemophilia a treated with factor VIII concentrates
Author(s) -
Schwarzinger Iise,
Pabinger Ingrid,
Korninger Christian,
Haschke Ferdinand,
Kundi Michael,
Niessner Herwig,
Lechner Klaus
Publication year - 1987
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.2830240303
Subject(s) - medicine , cumulative incidence , incidence (geometry) , risk factor , cumulative risk , cohort , pediatrics , physics , optics
Recent data published on the prevalence of inhibitors to factor VIII in hemophiliacs on treatment show great variations, with prevalence rates ranging from 3.6 to 14.2%. We have studied the cumulative risk of inhibitor development in a cohort of 62 patients with hemophilia A. All patients were born after 1960, were natives of the Vienna area, had a factor VIII activity of less than 5%, and were treated at least once. Using the method of Cutler and Ederer, the cumulative risk of inhibitor development was found to be 24% at the age of 25 years. Most inhibitors developed between the ages of 3 and 7 years. The current prevalence of F VIII inhibitors in the group of patients studied is 17.5%. It is concluded that prevalence data underestimate the true risk of inhibitor development.